Exporting Cannabis to Europe: What Producers Outside the EU Need to Get Right

There is no single European export route

Companies outside the European Union often describe their objective as exporting cannabis to Europe. In regulatory terms that objective does not exist. There is no single European authorisation, no single import licence and no single buyer category. Each Member State applies its own national rules alongside the relevant EU frameworks, with the balance between EU and national requirements depending on the product category.

The practical consequence is that an export plan has to be written for one destination country, one product category and one route to market. A plan that is written for Europe in general tends to collapse at the first authorisation question.

Start with the product category, not the shipment

Before anything else, establish which regulatory category your product falls into in the destination country. The categories are not interchangeable, and they carry very different requirements.

Medicinal cannabis and cannabis-based medicinal products fall within the EU medicines framework and national narcotics rules. Industrial hemp is governed by agricultural rules and national implementation. Consumer cannabinoid products may be treated as food, novel food, cosmetics or medicinal products depending on formulation, presentation and intended use. Adult-use frameworks, where they exist, are primarily national and may impose additional restrictions on cultivation, manufacture, distribution and sourcing from third countries.

A product can be classified differently in two neighbouring countries. Classification is a destination-country question and should be confirmed in writing before commercial discussions progress.

Legality at origin does not transfer

A licence, permit or product status held in the country of origin does not automatically transfer to an EU or EEA country. Producers in North America, Latin America, Africa and Oceania regularly assume the opposite, because domestic legality feels like the hard part of the problem.

For medicinal products within the scope of the EU medicines framework, importing from a third country requires an appropriate manufacturing authorisation covering the import operation. The authorisation is held by the EU-based importer, rather than by the exporter in the third country. In addition, cannabis remains subject to international drug-control conventions, so shipments of controlled material may require import and export authorisations issued by the competent national authorities at both ends.

Understand what the acronyms actually cover

GACP, GMP, EU-GMP, GDP, wholesale authorisation, import authorisation, marketing authorisation and product registration are distinct concepts. Their relevance depends on the product, its regulatory classification, the stage of the supply chain and the destination market.

In broad terms, good agricultural and collection practice relates to cultivation and primary processing of plant material where relevant to the regulatory route. Good manufacturing practice relates to manufacturing and quality systems for medicinal products. Good distribution practice relates to wholesale distribution. Import and wholesale authorisations are permissions held by named establishments. A marketing authorisation or a national product registration concerns a specific product placed on a specific market.

Where medicinal products are concerned, batch certification by a Qualified Person (QP) is part of the EU/EEA pharmaceutical framework. For products imported from third countries, the relevant certification takes place at the authorised importing site in the EEA. Being certified at origin does not remove that step.

Your route to market is your partner

In most European countries a third-country producer does not sell directly. Access is held by a domestic establishment with the relevant authorisations: an importer, a pharmaceutical wholesaler, a manufacturer or a specialised distributor. In practice, choosing that partner is choosing your market access, your pricing structure and a large part of your compliance exposure.

This is why partner diligence deserves more time than product presentation. The questions worth answering early are which authorisations the partner actually holds and for which activities, whether they have imported comparable material before, which customers they reach, and what documentation they will require before a first shipment.

Documentation is the real qualification round

European buyers in regulated supply chains assess suppliers on evidence, not capability claims. Certificates of analysis from an appropriate laboratory, a clear specification, batch-to-batch consistency data, stability information where relevant, packaging and labelling that meets destination requirements, and a documented chain of custody are usually decisive.

Buyers are also assessing reliability: whether you can repeat a batch, hold a specification, and supply at an agreed volume over time. A single good harvest is not a supply relationship. Our article on what European cannabis importers look for in a new supplier sets out that evaluation in detail.

Then test the commercial case

A route can be legal and still be uncommercial. The question that decides an export programme is not only whether the product can be supplied, but whether it can be supplied reliably and profitably through the chosen destination market.

Work the numbers through the whole chain: landed cost after freight, duties and testing; the partner margin; the price the destination channel actually pays; and the cost of the documentation and quality work required to stay in the market. Price levels differ considerably between European countries, and a model built on one country's pricing often fails in another.

A workable sequence

For most producers outside Europe, the sequence that works is narrow before broad.

• Choose one destination country and one product category.
• Confirm how that product is classified there, in writing.
• Identify which authorisations the route requires and who holds them.
• Shortlist domestic partners who already hold those authorisations.
• Assemble the documentation package a buyer there will ask for.
• Model landed cost and margin against real destination price levels.
• Run one controlled first shipment before scaling commitments.

Where to get help

We work with international producers and exporters on exactly this sequence: destination selection, regulatory route mapping, partner identification and the commercial model behind a European supply relationship.

If you are assessing a European export programme, the market entry calculator gives an initial view of scope and cost, and a short conversation will usually establish whether the route you are considering is viable.